Aims: A post-hoc analysis to assess the impact in people with type 2 diabetes, of increasing doses of basal insulin on glycaemic measures, body weight and hypoglycaemia.
| INTRODUCTION
It has been estimated that more than 30 million people in the United States,~9.4% of the total US population, are living with diabetes.
1 Of these, the majority has type 2 diabetes. 1 Given the progressive loss of β-cell function in type 2 diabetes, most patients will eventually require insulin therapy to achieve and maintain glycaemic targets. 2 The introduction of basal insulin analogues more than a decade ago has made it easier for primary care physicians to engage in the treatment of insulin-requiring patients and to intensify insulin therapy, with lower rates of hypoglycaemia achieved compared with non-modified human insulins. 3 This is critically important because~90% of type 2 diabetes care is carried out in the primary care setting. 4, 5 Treat-to-target titration trials have helped define the initiation and titration of basal insulin analogues contingent on achieving fasting plasma glucose (FPG) targets. [5] [6] [7] [8] [9] However, although basal insulin provides a steady level of insulin throughout the day and helps to control FPG levels by lowering baseline plasma glucose, it has no direct effect on postprandial plasma glucose (PPG). 10, 11 As diabetes progresses, β-cell function diminishes, resulting in greater PPG excursions and high levels of glycated *Deceased 6 June 2016.
haemoglobin (HbA1c). 12, 13 Increasing basal insulin doses in such patients has limited effect on PPG, and higher doses may result in "over-basalization," 12 which has been reported to increase the risk of hypoglycaemia and weight gain. 12, 13 At this point, treatment intensification is required. 
| RESEARCH DESIGN AND METHODS

| Study selection population
Data from participants in eligible studies were included in the analysis.
Studies were eligible if they were at least 24 weeks in length and were prospective, randomized controlled treat-to-target trials, with protocol titration algorithms targeting an FPG <5.6 mmol/L (100 mg/dL) ( Figure S1 , Supporting Information). For inclusion in the present analysis, participants were required to have type 2 diabetes inadequately controlled on insulin glargine U100 in combination with metformin and a sulphonylurea and to have had at least six measurements of FPG taken during the study.
| Outcomes
The HbA1c 
| Statistical analysis
Participant demographics, baseline characteristics and clinical outcomes were summarized descriptively. The changes in FPG and
HbA1c from baseline to study endpoint were calculated across all insulin doses, and additionally for each incremental 0.1-IU/kg/d dose increase, from ≤0.3 to 0.7 IU/kg/d. Assessment of the number of participants reaching HbA1c <7.0% at study endpoint was limited to participants with a baseline HbA1c ≥53 mmol/mol (7.0%). Overall incidence of hypoglycaemia was assessed for the entire study period, also categorized by final insulin dose. Rates of daytime, nocturnal and severe hypoglycaemia have been previously assessed for this study population and are presented elsewhere. 21 An evaluation of change in body weight was made, categorized for the participants who 3 | RESULTS
| Participant demographics and clinical characteristics
A total of 63 trials of insulin glargine U100 performed between 1997 and 2007 were assessed for inclusion ( Figure S1 , Supporting Information). Three studies met the inclusion criteria, 6, 22, 23 and data from these were pooled (Table S1 , Supporting Information). A total of 458 participants who had FPG data available at both baseline and endpoint were included in the final analysis. Baseline characteristics are shown in Table 1 .
| Changes in FPG with increasing insulin dose
The mean daily insulin starting dose at baseline was 10. 
| Effects on hypoglycaemia and weight change
The incidence of hypoglycaemia was broadly similar across insulin doses, ranging from~55% to 75% of participants, with no significant differences between insulin doses ≤0. 
| DISCUSSION
The present post hoc analysis of pooled data from three basal insulin increased risk of hypoglycaemia and greater weight gain. [24] [25] [26] In a pooled study of patient-level data from 15 randomized, treat-to-target trials in insulin-naive participants with type 2 diabetes treated with insulin glargine ± oral antidiabetes drugs for ≥24 weeks, data were stratified according to whether participants exceeded daily insulin dose thresholds >0.5, >0.7 and >1.0 IU/kg. 24 At week 24, participants with insulin titrated beyond the three thresholds had significantly higher mean HbA1c and FPG levels compared with participants at or In addition, participants who exceeded the thresholds also had greater weight gain and a higher likelihood of hypoglycaemia once the threshold was exceeded. 24 Both higher initial doses and increasing dose have been shown to be associated with weight gain. 25, 26 In the CREDIT (Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy) trial, 1 year after initiating insulin therapy, mean weight gain was 1.78 kg. 25 Participants who gained the most weight had higher insulin doses; after adjusting for other factors, an insulin dose of 0.6 IU/kg/d compared with 0.4 IU/kg/d at 1 year was associated with a 0.5-kg higher weight gain. 25 Consistent with these studies, we observed that increasing basal insulin doses >0.5 IU/kg/d had incrementally less effect on blood glucose reduction, but they led to a greater increase in weight. In the present study, however, there was a similar overall incidence of hypoglycaemia across insulin doses, contrary to that reported in previous studies. The reason for this is unclear, but it may relate to the titration regimen, whereby participants who experienced hypoglycaemia did not receive an increase in insulin dose. 
2,18
The limitations of the present study primarily relate to the fact that it is a post hoc analysis of pooled data from three studies not specifically designed to determine if there is a diminishing response to increasing basal insulin dose. Furthermore, specifying that participants required a background therapy of metformin and a sulphonylurea limited the number studies that could be included in the analysis. Participant numbers and cohorts were small and the frequency of laboratory assessment time points was limited in some cases, particularly for subgroup analyses, and dictated by trial protocols designed with different objectives. In addition, the total basal insulin dose included in this analysis was not adjusted for the presence of comorbidities or degree of insulin sensitivity in study participants. Finally, as only participants taking insulin glargine U100 were eligible to be included in the analysis, this limits extrapolation to other basal insulins such as the newer second-generation insulins, although these newer insulins have yet to be proven to be more efficacious than insulin glargine U100.
In summary, the present study indicates a non-linear clinical This manuscript is one of last publications that Charles Shaefer, MD participated in prior to his passing, please see Appendix S1 for an
In Memoriam.
